Clinical Trials in Viterbo, Italy
4 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
Colorectal, Cancer
Gruppo Oncologico del Nord-Ovest238 enrolled24 locationsNCT06733038
Recruiting
Prevention ICONA Dedicated Ensemble
HIV-1-infectionHIVPrEP+3 more
Fondazione ICONA5,000 enrolled53 locationsNCT07186244
Recruiting
Phase 3
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
High-risk MDS
Gruppo Italiano Malattie EMatologiche dell'Adulto274 enrolled46 locationsNCT04184505
Recruiting
EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase
Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS1,000 enrolled29 locationsNCT06894173
Recruiting
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
MyelofibrosisPrimary MyelofibrosisSecondary Myelofibrosis
IRCCS Azienda Ospedaliero-Universitaria di Bologna1,055 enrolled26 locationsNCT06516406
Recruiting
BRING-UP 3 Heart Failure
Heart Failure
Heart Care Foundation10,000 enrolled187 locationsNCT06279988
Recruiting
BRING-UP Prevention
Peripheral Arterial DiseaseCerebrovascular DisordersIschemic Heart Disease
Heart Care Foundation6,000 enrolled196 locationsNCT06275113
Recruiting
Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.
Myeloproliferative diseaseInflammatory Markers
University of Milano Bicocca500 enrolled11 locationsNCT05553873
Recruiting
Phase 2
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
Metastatic Renal Cell Carcinoma
Consorzio Oncotech118 enrolled23 locationsNCT05817903